Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries
Ist Teil von
European journal of clinical pharmacology, 2017-08, Vol.73 (8), p.957-963
Ort / Verlag
Berlin/Heidelberg: Springer Berlin Heidelberg
Erscheinungsjahr
2017
Link zum Volltext
Quelle
SpringerNature Journals
Beschreibungen/Notizen
Purpose
Rocuronium (ROC) is a neuromuscular blocker mainly eliminated by biliary excretion dependent on organic anion transporting polypeptide 1A2 (OATP1A2) hepatocellular uptake. However, the influence of
SLCO1A2
(gene encoding OATP1A2) genetic polymorphism on ROC pharmacokinetics was never described before. The objective of this work was to evaluate the influence of genetic polymorphisms of
SLCO1A2
on the pharmacokinetics of rocuronium (ROC).
Methods
Patients undergoing elective surgeries under general anesthesia using rocuronium as a neuromuscular blocker were genotyped for
SLCO1A2
polymorphisms in the coding region (41A>G, 382A>T, 404A>T, 502C>T, 516A>C, 559G>A, 830C>A, and 833delA) and in the promoter region (-1105G>A, -1032G>A, -715T>C, -361G>A, and -189_-188insA). Rocuronium pharmacokinetic parameters were estimated by non-compartmental analysis.
Results
None of the patients had heterozygous or homozygous variant of 404A>T, 382A>T, 502C>T, 833delA, 830C>A, 41A>G, and -715T>C. A linkage disequilibrium was found between -1105G>A and -1032G>A genotypes. Patients genotyped as -A or AA (
n
= 17) for
SLCO1A2
-189_-188InsA showed reduced total clearance of ROC compared to patients genotyped as −/− (
n
= 13) (151.6 vs 207.1 mL/min,
p
≤ 0.05). The pharmacokinetics parameters of ROC were not significantly different between other
SLCO1A2
genotypes.
Conclusion
SLCO1A2
-189_-188InsA polymorphism is related to the reduced clearance of rocuronium in patients submitted to elective surgeries under general anesthesia.
Trial registration
NCT 02399397 (
ClinicalTrials.gov
)